Results 201 to 210 of about 58,972 (283)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Pediatric Sarcoidosis With Chronic Massive Splenomegaly and Renal Involvement: A Case Report. [PDF]

Case Rep Med
Mobayen G, Hiradfar A, Dastranji A, Lahouty M.   +3 more
europepmc   +1 more source

The Risk of Lymphoma in Inflammatory Bowel Disease and its Association With Immunosuppression: A Systematic Review and Meta‐Analysis

JCC Plus, Volume 1, Issue 4, July 2026.
ABSTRACT Background and Aims There is a recognised association between inflammatory bowel disease (IBD) and lymphoma. However, the magnitude of lymphoma risk and impact of immunosuppression remain uncertain. Existing syntheses are limited by pooling of Crohn's disease (CD) and ulcerative colitis (UC) risk, conflation of disease‐ and treatment ...
Robert D. Lees, Alexandra Hickey, Ryan P. W. Kenny, Christopher A. Lamb, Laura M. Woods, R. Ally Speight   +5 more
wiley   +1 more source

Model-Based Design of Sustained-Release Formulations of Anti-TNF-α Monoclonal Antibodies for Intravitreal Administration. [PDF]

Pharmaceutics
Reig-López J, Cuquerella-Gilabert M, Zarzoso-Foj J, Mangas-Sanjuán V, Merino V, Merino-Sanjuán M.   +5 more
europepmc   +1 more source

Treatment Outcomes of Hospitalized Patients With Inflammatory Bowel Disease at a Tertiary Care Center in Nepal: A Cross‐Sectional Study

JCC Plus, Volume 1, Issue 4, July 2026.
Overall, patients with IBD constituted 1.6% (n = 37) of all admissions to the gastroenterology ward for any indication. Most (2/3rd) hospitalized patients with IBD responded to conventional therapy; one third required advanced therapy or surgery. In‐hospital mortality was high at 5%, probably related to delayed diagnosis, limited access to advanced ...
Ajay Kumar Yadav, Bhupendra Kumar Basnet, Ramila Shrestha, Ajit Khanal, Milan Shrestha, Mukesh Sharma Poudel   +5 more
wiley   +1 more source

The Safety of Treating Women With Inflammatory Bowel Disease With Allopurinol and Low‐Dose Thiopurine During Pregnancy: A Single‐Center Experience

JCC Plus, Volume 1, Issue 4, July 2026.
ABSTRACT Background Low‐dose thiopurine therapy in combination with allopurinol (LD‐THIO/ALLO) is a widely used treatment for inflammatory bowel disease (IBD). However, little is known about the effects of in utero exposure to this combination on pregnancy and birth outcomes.
Kavitha Sivananthan, Signe Wildt, Marianne Kiszka‐Kanowitz, Gitte Pedersen, Ida Vind, Inge Nordgaard‐Lassen, Andreas Munk Petersen, Johan Burisch, Helle Kristensen, Klaus Theede   +9 more
wiley   +1 more source

Effects of Infliximab in a Propionic Acid-Induced Experimental Autism Rat Model. [PDF]

Biomedicines
Akman N, Kömüroğlu AU, Çibuk S, Altındağ F, Yılmaz O, Ateşşahin A.   +5 more
europepmc   +1 more source

Sustained Treatment Success With Ustekinumab in Symptomatic Stricturing Crohn's Disease: A Retrospective Single‐Arm Observational Cohort Study

MedComm, Volume 7, Issue 7, July 2026.
Data on ustekinumab (UST) for symptomatic stricturing Crohn's disease remain scarce in China. This cohort study screened 73 patients from June 2022 to April 2024, of whom 54 were eligible included, with 81.5% achieving 52‐week treatment success. Most attained sustained clinical remission alongside improved inflammation and strictures. Nonsmoking status
Jingwen Liu, Wen Hu, Shuyan Li, Shurong Hu, Deming Jiang, Yan Chen   +5 more
wiley   +1 more source

Different treatments for Crohn's disease complicated by severe acute lower gastrointestinal bleeding: infliximab therapy is critical and cannot be ignored. [PDF]

Front Pharmacol
Yao S, Wang Z, Xie M, Wu S, Feng Y, Liu X, Wang F.   +6 more
europepmc   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 103-111, July 2026.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source